WASHINGTON, April 22 (Reuters) - The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals (VNDA.O), opens new tab to revive patents for its sleep-disorder drug Hetlioz that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results